tradingkey.logo

Sanofi SA

SNY
查看詳細走勢圖
46.290USD
0.0000.00%
收盤 01/28, 16:00美東報價延遲15分鐘
112.68B總市值
11.20本益比TTM

Sanofi SA

46.290
0.0000.00%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

+0.24%

1月

-4.50%

6月

-6.45%

今年開始到現在

-4.48%

1年

-12.61%

查看詳細走勢圖

TradingKey Sanofi SA股票評分

單位: USD 更新時間: 2026-01-28

操作建議

Sanofi SA當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名55/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為59.64。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Sanofi SA評分

相關信息

行業排名
55 / 159
全市場排名
159 / 4540
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Sanofi SA亮點

亮點風險
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
高分紅
公司屬於高分紅公司,最新股息支付率171.67%
穩定分紅
公司5年內持續分紅,最新股息支付率171.67%
估值低估
公司最新PE估值11.07,處於3年歷史低位
機構減倉
最新機構持股240.38M股,環比減少9.29%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉34.20K股

分析師目標

基於 10 分析師
買入
評級
59.643
目標均價
+26.36%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Sanofi SA新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Sanofi SA簡介

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
公司代碼SNY
公司Sanofi SA
CEOHudson (Paul)
網址https://www.sanofi.com/
KeyAI